Loading…
.jpg%3Fwidth%3D800&w=640&q=75)
thyroid medullary carcinoma
malignant thyroid neoplasm originating from C-cells
Details
- Instance of
- type of disease
- Subclass of
- follicular thyroid cancer, medullary carcinoma
- drug or therapy used for treatment
- vandetanib, cabozantinib, lenvatinib
- genetic association
- RET
- health specialty
- oncology
- ICPC 2 ID
- T71
Connected on Wikidata
Subject of
- Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
- Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
- Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
- The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
- A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
- An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
- A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
- An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
- Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Nothing in the MetaHistoryBook collection references this item yet.